Sun Pharmaceutical Gains 1.02%: 5 Key Factors Driving the Week’s Momentum

23 March 2026: Market Sell-Off Weighs on Sun Pharma

Sun Pharmaceutical Industries Ltd opened the week under pressure, closing at Rs.1,756.35, down 1.19% (Rs.21.10) amid a sharp Sensex decline of 3.13%. The stock’s volume was relatively low at 50,741 shares, reflecting cautious investor sentiment. The broad market sell-off, driven by macroeconomic concerns, impacted large caps including Sun Pharma, which underperformed the index but maintained technical support above key moving averages.

24 March 2026: Open Interest Surges Amid Mixed Signals

Despite a slight price decline of 0.20% to Rs.1,752.80, Sun Pharma saw a notable 13.37% increase in open interest in its derivatives segment, rising to 1,28,548 contracts. Futures volume was robust at 85,090 contracts, with combined futures and options value approximating ₹18,189 crores. This surge in open interest, alongside a delivery volume increase of 18.06% to 20.15 lakh shares, indicated growing investor participation and evolving positioning despite short-term price weakness.

Sun Pharma underperformed the Pharmaceuticals & Biotechnology sector, which gained 1.03%, and the Sensex, which rose 1.95%. The stock’s technical picture was mixed, trading below its 5-day and 20-day moving averages but above longer-term averages, signalling consolidation amid heightened market activity.

25 March 2026: Strong Intraday Rally and Derivatives Momentum

Sun Pharma rebounded sharply, closing at Rs.1,794.85, up 2.40% (Rs.42.05), with an intraday high of Rs.1,805.90, a 3.08% surge from the previous close. This rally outpaced the Pharmaceuticals & Biotechnology sector’s 2.49% gain and the Sensex’s 1.93% rise, signalling renewed buying interest and technical strength.

Derivatives activity intensified with open interest rising 12.54% to 1,28,826 contracts and futures volume reaching 1,01,018 contracts. The total derivatives value traded was approximately ₹1,79,974.15 lakhs, reflecting robust liquidity and investor confidence. The stock traded above all major moving averages, reinforcing a strong bullish trend.

However, delivery volumes declined by 17.07% to 14.92 lakh shares, suggesting that short-term traders and speculators were driving the momentum rather than long-term accumulation. The stock’s proximity to its 52-week high of Rs.1,851.20 underscored a key resistance level to watch.

27 March 2026: Call Option Activity Peaks Ahead of Expiry

As expiry approached on 30 March, Sun Pharma emerged as the most active stock in call options trading, particularly at the Rs.1,820 strike price, with 14,049 contracts traded and a turnover of ₹29.31 crores. Open interest at this strike stood at 3,589 contracts, indicating sustained bullish positioning.

The stock closed at Rs.1,795.65, just 2.9% below its 52-week high, gaining 0.04% on the day despite a 2.11% Sensex decline. Derivatives open interest surged 10.83% to 1,25,691 contracts, with total derivatives value exceeding ₹1,63,293 lakhs. The stock maintained its position above all key moving averages, signalling continued technical strength.

Delivery volumes remained subdued, down 38.04% compared to the five-day average, highlighting a divergence between price gains and underlying investor participation. This suggests that the rally was largely driven by speculative and short-term trading activity in the derivatives market.

Key Takeaways

Positive Signals: Sun Pharma outperformed the Sensex by 2.48% over the week, closing near its 52-week high with strong technical positioning above all major moving averages. The consistent surge in derivatives open interest and call option activity ahead of expiry reflects growing bullish sentiment and fresh capital inflows. The upgraded Mojo Score of 72.0 and Buy grade reinforce the stock’s improving fundamentals and market confidence.

Cautionary Notes: Despite price gains, delivery volumes declined notably, indicating that the rally was driven more by speculative and short-term trading rather than broad-based accumulation. The divergence between derivatives activity and cash market participation suggests potential volatility ahead. Investors should monitor price action around key resistance levels, particularly the Rs.1,820 strike price in options, and remain mindful of broader market fluctuations.

Conclusion

Sun Pharmaceutical Industries Ltd demonstrated resilience and relative strength during a volatile week, gaining 1.02% while the Sensex declined 1.46%. The stock’s performance was underpinned by robust derivatives market activity, including significant open interest surges and call option turnover ahead of expiry, signalling bullish market positioning. Technical indicators remain favourable, with the stock trading above all key moving averages and close to its 52-week high.

However, the decline in delivery volumes highlights a divergence between price momentum and underlying investor participation, suggesting that the current rally may be driven by short-term traders. Market participants should continue to monitor derivatives trends alongside price and volume data to assess the sustainability of the uptrend. Overall, Sun Pharma remains a key large-cap pharmaceutical stock exhibiting strong market engagement and technical strength amid mixed broader market conditions.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today